Contact Us
Drug Search Results
More Filters [+]

Pegfilgrastim

Alternative Names: pegfilgrastim, neulasta, udenyca, fulphila, fylnetra, stimufend
Latest Update: 2024-08-29
Latest Update Note: Clinical Trial Update

Product Description

Pegfilgrastim is a covalent conjugant of filgrastim (a recombinant human granulocyte colony-stimulating factor) and monomethoxypolyethylene glycol. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12010086/)

Mechanisms of Action: G-CSF

Novel Mechanism: No

Modality: Coagulation Factor

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela | Vietnam

Approved Indications: Febrile Neutropenia | Neutropenia | Oncology Unspecified | Hematopoietic Stem Cell Transplant | Stem Cell Transplant

Known Adverse Events: Pain Unspecified

Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Pegfilgrastim

Countries in Clinic: Australia, China, France, Japan, New Zealand, United States

Active Clinical Trial Count: 7

Highest Development Phases

Phase 3: Neutropenia

Phase 2: Breast Cancer|Hepatitis B, Chronic|Intestinal Diseases|Lymphoma|Multiple Myeloma

Phase 1: Febrile Neutropenia|Hematopoietic Stem Cell Transplant

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
BREASTIMMU02

P2

Recruiting

Breast Cancer

2025-01-01

jRCT2011210029

P2

Completed

Multiple Myeloma|Lymphoma

2022-10-31

ACTRN12620000657921

P1

Completed

Neutropenia

2021-02-08

2006-7041-83/hah

P2

Not yet recruiting

Intestinal Diseases|Hepatitis B, Chronic

None

Recent News Events

Date

Type

Title

09/04/2024

News Article

 Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry

08/26/2024

News Article

 Aplastic Anemia Market Size & Share to Surpass USD 10.8 Billion by 2034, at a CAGR 4.3% - Transparency Market Research, Inc.

07/25/2024

News Article

 Kashiv BioSciences Announces Completion of Enrollment for Phase III Clinical Trial of ADL018, a Biosimilar Candidate to XOLAIR® (omalizumab)

07/22/2024

News Article

 Biosimilar Market to Surpass $102.68 Billion by 2034 with 8.9% Annual Growth, Says Fact.MR

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions